Navigation Links
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Date:2/7/2008

SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.

The Phase III trial has been designed as a global, randomized, multi-center open label trial to prospectively evaluate the safety and efficacy of Karenitecin compared to the chemotherapy drug topotecan (also known as Hycamtin(R)). Either Karenitecin or topotecan will be given intravenously daily for 5 consecutive days repeated every 3 weeks to advanced ovarian cancer patients who have previously been treated with platinum and taxane chemotherapy drugs but have become resistant to the platinum/taxane therapy. BioNumerik has received written agreement from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) regarding the clinical trial design and protocol.

Four Phase II clinical trials of intravenously administered Karenitecin have been completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced non-small cell lung cancer, and primary brain tumors. BioNumerik has also initiated a Phase I clinical trial to evaluate the safety and effectiveness of an orally administered Karenitecin formulation. Based on prior studies, BioNumerik believes Karenitecin may have the following potential advantages over currently marketed camptothecins:
-- Comparable or improved effectiveness in the treatment of certain

cancers, with a potentially improved
'/>"/>

SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... MIAMI , Oct. 1, 2014 NeuroCall, ... Commission accreditation for its Telestroke and Teleneurology services. Dr. ... of NeuroCall, commented, "We are extremely proud that our ... Commission, as we continue to provide lifesaving support and ... of affiliated hospitals throughout the United States ...
(Date:10/1/2014)... LOUIS , Oct. 1, 2014  Express Scripts ... two nationally available 2015 Express Scripts Medicare ® ... pharmacy network featuring Walgreens (NYSE: WAG ) ... more value, choice and clinical support  for their Medicare ... Express Scripts Medicare Value or Choice ...
(Date:10/1/2014)... , Oct. 1, 2014 ... a clinical-stage biopharmaceutical company focused on cardio-renal, ... results from its 371 patient Phase 2b ... constipation-predominant irritable bowel syndrome (IBS-C).  Results from ... meaningful improvement in IBS-C symptoms for tenapanor-treated ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Berkery Noyes announced today that the,firm represented The Thomson ... sale,of CenterWatch ("CW") and New England Institutional Review Board ... Wicks Group, LLC.,Terms of the transaction were not disclosed., ... and global leader in,providing proprietary data and information about ...
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... in the 500 mg strength. Watson,s Clarithromycin,Extended-Release product ... is indicated to treat or prevent infections that ... susceptible bacteria. For the 12-months,ending September 2007, Biaxin(R) ...
Cached Medicine Technology:Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information 2Watson Launches Generic Biaxin(R) XL 2
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected as ... American Made Awards (MSAMAs), an annual competition in recognition ... fields of crafts, design, food and style. , ... the MSAMAs, which celebrates entrepreneurs and artisans who are ... and changing the way we shop, work and live,” ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the world’s ... to Chennai, India, tomorrow to speak at the Indian ... , Dr. Jivraj is founder of the Anacapa Dental ... one of the world’s foremost prosthodontists, meaning he is ... speaking to the Indian Society of Oral Implantologists about ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... device company publicly traded on the Tel-Aviv Stock Exchange (TASE: ... Journal of Human Hypertension . The advance online publication ... The study will also be published in the May issue ... of RESPeRATEthe only medical device cleared by the FDA and ...
... March 9 Surgical Information Systems (SIS) unveils SIS ... tissue lifecycle and provides the means for hospitals to ... tissues. The first tissue tracking solution to be ... manages tissue in a manner that enables hospitals to ...
... March 9 President Obama signed an ... human embryonic stem cell research, overturning limits on federal ... Charmaine Yoest, President & CEO of Americans United for ... of the past. Millions of dollars have been ...
... The Christopher & Dana Reeve Foundation joins millions ... previous restrictions on federal funding of human embryonic stem ... the Reeve Foundation, stated, "With a stroke of his ... of Americans and harnessed the power of the federal ...
... Delays and Unnecessary StaysCOLLEGE PARK, Md., March 9 ... H. Smith School of Business put a price tag on ... billion per year. The research, newly released from the Center ... to quantify the economic impact of a health care system ...
... YORK, Pa., March 9 The Danone Baby Nutrition ... bottle manufacturing plant in Zoetermeer, the Netherlands, as the ... is the equivalent of a supplier-of-the-year award and is ... at all levels -- during 2008," said Rafael Fernandez, ...
Cached Medicine News:Health News:New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients 2Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2Health News:Christopher & Dana Reeve Foundation Commends President Obama's Decision to Lift Federal Restrictions on Stem Cell Research 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3Health News:Graham Packaging On-Site Plant in Zoetermeer Wins Top Performance Award From The Danone Baby Nutrition and Medical Nutrition Divisions 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: